306296-72-0

Upstream product

• 306297-06-3 C₁₅H₂₀O₂ 
• 68-12-2 N,N-dimethyl-formamide 
• 74346-19-3 4-bromo-2,6-dimethylbenzoic acid 

Downstream Products

• 306296-76-4 2,6-dimethyl-4-formyl benzoic acid 
• 306297-08-5 C₁₄H₁₈F₂O₂ 
• 306297-20-1 2,6-dimethyl-terephthalic acid mono-tert-butyl ester 

Relevant academic research and scientific papers

MACROCYCLIC COMPOUND AND USE THEREOF

A compound represented by the following formula (I): wherein each symbol in the formula is as described herein or a salt thereof has an NRF2 activating activity, and is expected to be useful as a preventive or therapeutic agent for diseases associated with oxidative stress, in particular, hepatic disease (for example, non-alcoholic steatohepatitis (NASH)), cardiovascular disease (for example, heart failure or pulmonary arterial hypertension), lung disease (for example, chronic obstructive pulmonary disease (COPD)), kidney disease (for example, chronic kidney disease (CKD) or acute kidney injury (AKI)), central nervous system disease (for example, Parkinson's disease), mitochondrial disease (for example, Friedreich motor ataxia, mitochondrial myopathy), inflammatory disease (for example, multiple sclerosis (MS), inflammatory bowel disease (IBD)), sickle cell disease, cancer, or the like.

PIPERAZINE DERIVATIVES USEFUL AS CCR5 ANTAGONISTS

The use is described of CCR5 antagonists of formula (I) or a pharmaceutically acceptable salt thereof, wherein: R is optionally substituted phenyl, pyridyl, thiophenyl or naphthyl; R 1 is hydrogen or alkyl; R 2 is substituted phenyl, substituted heteroary

Piperazine derivatives useful as CCR5 antagonists

The use of CCR5 antagonists of the formula or a pharmaceutically acceptable salt thereof, wherein R is optionally substituted phenyl, pyridyl, thiophenyl or naphthyl; R1is hydrogen or alkyl; R2is substituted phenyl, substituted heter